KPTI - Karyopharm Therapeutics: Spiraling Despite Upcoming Catalysts

2024-04-30 14:28:23 ET

Summary

• Karyopharm Therapeutics Inc.'s selinexor is being featured in 7 presentations at ASCO.
• The company is also exploring selinexor's potential role in myelofibrosis, with two key trials planned.
• Karyopharm Therapeutics' cash position is a challenge, but success in any of their pivotal trials could be a game changer for selinexor's prospects.

Topline Summary and Update

Karyopharm Therapeutics Inc. ( KPTI ) is a long-struggling commercial-stage biotech working on developing the market for their nuclear exportin 1 inhibitor selinexor. While it is currently approved to treat multiple myeloma in later lines of therapy, KPTI is on track to potentially expand the label into endometrial cancer, with a phase 3 trial eagerly anticipated (though still a ways away)....

For further details see: